Parkinson’s Disease: Where Are We?

Parkinson's Disease

Volumn , Issue , 2004, Pages 27-38

  Kumar, Ajit ^a   Huang, Zhigao ^a   Calne, Donald B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85160140772     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-14     Document Type: Chapter

References (141)

1. Calne, D. B., Parkinson’s disease is not one disease, Parkinsonism Relat. Disord. 2001; 7:3-7.
2. Furtado, S., Farrer, M., Tsuboi, Y., Klimek, M. L., Fuente-Fernandez, R, Hussey, J., et al., SCA-2 presenting as parkinsonism in an Alberta family: Clinical, genetic, and PET findings, Neurology, 59(10):1625-1627, 2002.
3. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., et al., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 392(6676):605-608, 1998.
4. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease, Nat Genet; 18(2):106-108, 1998.
5. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al., Mutation in the alphasynuclein gene identified in families with Parkinson’s disease, Science, 276(5321):2045-2047, 1997.
6. Huang, Z., Fuente-Fernandez, R., Stoessl, A. J., Etiology of Parkinson’s disease, Can. J. Neurol. Sci., 30 Suppl. 1:S10-S18, 2003.
7. Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., Kortsha, G. X., Brown, G. G., et al., Occupational exposures to metals as risk factors for Parkinson’s disease. Neurology, 48(3):650-658, 1997.
8. Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., Richardson, R. J., The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living, Neurology, 50(5):1346-1350, 1998.
9. Lai, B. C. L., Marion, S. A., Teschke, K., Tsui, J. K. C., Occupational and environmental risk factors for Parkinson’s disease, Parkinsonism Relat. Disord., 8:297-309, 2002.
10. Zorzon, M., Capus, L., Pellegrino, A., Cazzato, G., Zivadinov, R., Familial and environmental risk factors in Parkinson’s disease: A case-control study in north-east Italy, Acta Neurol. Scand., 105(2):77-82, 2002.
11. Calne, D. B., Langston, J. W., Aetiology of Parkinson’s disease, Lancet, 2(8365-66):1457-1459, 1983.
12. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., et al., The ubiquitin pathway in Parkinson’s disease, Nature, 395(6701):451-452, 1998.
13. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., et al., Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism, Science, 299(5604):256-259, 2003.
14. Gasser, T., Muller-Myhsok, B., Wszolek, Z. K., Oehlmann, R, Calne, D. B., Bonifati, V., et al., A susceptibility locus for Parkinson’s disease maps to chromosome 2p13, Nat Genet, 18(3):262-265, 1998.
15. Farrer, M., Gwinn-Hardy, K., Muenter, M., DeVrieze, F. W., Crook, R., Perez-Tur, J., et al., A chromosome 4p haplotype segregating with Parkinson’s disease and postural tremor, Hum. Mol. Genet., 8(1):81-85, 1999.
16. Valente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., Albanese, A., and Wood, N. W., Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36, Am. J. Hum. Genet., 68(4):895-900, 2001.
17. Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., Obata, F., A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol., 51(3):296-301, 2001.
18. Scott, W. K., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Lyons, K., et al., Complete genomic screen in Parkinson disease: Evidence for multiplegenes. JAMA, 286(18):2239-2244, 2001.
19. Mouradian, M. M., Recent advances in the genetics and pathogenesis of Parkinson disease, Neurology, 58(2):179-185, 2002.
20. Shastry, B. S., Parkinson disease: Etiology, pathogenesis and future of gene therapy, Neurosci. Res., 41(1):5-12, 2001.
21. Takahashi, H., Ohama, E., Suzuki, S., Horikawa, Y., Ishikawa, A., Morita, T., et al., Familial juvenile parkinsonism: Clinical and pathologic study in a family, Neurology, 44(3 Pt. 1):437-441, 1994.
22. Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R., et al., Parkinson disease in twins: An etiologic study, JAMA, 281(4):341-346, 1999.
23. de la Fuente-Fernandez, R., Calne, D. B., Evidence for environmental causation of Parkinson’s disease, Parkinsonism Relat. Disord., 8(4):235-241, 2001.
24. Kurtzke, J. F., Goldberg, I. D., Parkinsonism death rates by race, sex, and geography, Neurology, 38(10):1558-1561, 1998.
25. Langston, J. W., Forno, L. S., Rebert, C. S., Irwin, I., Selective nigral toxicity after systemic administration of 1-methyl-4phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey, Brain Res., 292(2):390-394, 1984.
26. Vingerhoets, F. J., Snow, B.J., Tetrud, J. W., Langston, J. W., Schulzer, M., Calne, D. B., Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions, Ann. Neurol., 36(5):765-770, 1994.
27. Menegon, A, Board, P. G., Blackburn, A. C., Mellick, G. D., Le Couteur, D. G., Parkinson’s disease, pesticides, and glutathione transferase polymorphisms, Lancet, 352(9137):1344-1346, 1998.
28. Semchuk, K. M., Love, E. J, Effects of agricultural work and other proxy-derived case-control data on Parkinson’s disease risk estimates, Am. J. Epidemiol., 141(8):747-754, 1995.
29. Priyadarshi, A., Khuder, S. A., Schaub, E. A., Shrivastava, S., A meta-analysis of Parkinson’s disease and exposure to pesticides, Neurotoxicology, 21(4):435-440, 2000.
30. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., Greenamyre, J. T., Chronicsystemic pesticide exposure reproduces features of Parkinson’s disease, Nat. Neurosci., 3(12):1301-1306, 2000.
31. Rajput, A. H., Uitti, R. J., Stern, W., Laverty, W., Early onset Parkinson’s disease in Saskatchewan—environmental considerations for etiolog., Can. J. Neurol. Sci., 13(4):312-316, 1986.
32. Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., Kortsha, G. X., Brown, G. G., et al., Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson’s disease, Neurotoxicology, 20(2-3):239-247, 1999.
33. Tanner, C. M., Goldman, S. M., Aston, D. A., Ottman, R., Ellenberg, J., Mayeux, R., et al., Smoking and Parkinson’s disease in twins, Neurology, 58(4):581-588, 2002.
34. Golbe, L. I., Langston, J. W., The etiology of Parkinson’s disease: New directions for research. Jankovic, J., Tolosa, E., Eds., Parkinson’s disease and movement disorders, Williams and Wilkins, Baltimore, MD, 93-101, 1993.
35. Baron, J. A., Cigarette smoking and Parkinson’s disease, Neurology, 36(11):1490-1496, 1986.
36. Maggio, R., Riva, M., Vaglini, F., Fornai, F., Molteni, R., Armogida, M., et al., Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors, J. Neurochem., 71(6):2439-2446, 1998.
37. Ross, G. W., Abbott, R. D., Petrovitch, H., Morens, D. M., Grandinetti, A., Tung, K. H., et al., Association of coffee and caffeine intake with the risk of Parkinson disease, JAMA, 283(20):2674-2679, 2000.
38. Chen, J. F., Xu, K., Petzer, J. P., Staal, R., Xu, YH., Beilstein, M., et al., Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease, J. Neurosci., 21(10):RC143, 2001.
39. Ross, G. W., Petrovitch, H., Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson’s disease, Drugs Aging, 18(11):797-806, 2001.
40. Duvoisin, R. C., Yahr, M. D., Encephalitis and parkinsonism, Arch. Neurol., 112:227-239, 1985.
41. Calne, D. B., Lees, A. J., Late progression of postencephalitic Parkinson’s syndrome, Can. J. Neurol. Sci., 15(2):135-138, 1988.
42. Lin, S. K., Lu, C. S., Vingerhoets, F. J., Snow, B. J., Schulzer, M., Wai, Y. Y., et al., Isolated involvement of substantia nigra in acute transient parkinsonism: MRI and PET observations, Parkinsonism Relat. Disord., 1(2):67-73, 1995.
43. Takahashi, M., Yamada, T., Viral etiology for Parkinson’s disease—a possible role of influenza A virus infection, Jpn. J. Infect. Dis., 52(3):89-98, 1999.
44. Yamada, T., Yamanaka, I., Takahashi, M., Namajima, S., Invasion of brain by neurovirulent influenza A virus after intranasal inoculation, Parkinsonism Relat. Disord., 2(4):187-193, 1996.
45. Yamada, T., Yamanaka, I., Takahashi, M., Namajima, S., Invasion of brain by neurovirulent influenza A virus after intranasal inoculation, Parkinsonism Relat. Disord., 2(4):187-193, 1996.
46. Woulfe, J., Hoogendoorn, H., Tarnopolsky, M., Munoz, D. G., Monoclonal antibodies against Epstein-Barr virus cross-react with alphasynuclein in human brain, Neurology, 55(9):1398-1401, 2000.
47. McGeer, P. L., Yasojima, K., McGeer, E. G., Inflammation in Parkinson’s disease, Adv. Neurol., 86:83-89, 2001.
48. McGeer, P. L., Yasojima, K., McGeer, E. G., Association of interleukin 1a polymorphisms with idiopathic Parkinson’s disease, Neurosc. Lett., 326(1):67-69, 2002.
49. McGeer, P. L. and McGeer, E. G., Inflammation and neurodegeneration in Parkinson’s disease, Parkinsonism Relat. Disord., 10(Suppl. 1):S3-7, 2004.
50. Tanner, C. M., Goldman, S. M., Quinlan, P., Field, R., Aston, D. A., Comyns, K., et al., Occupation and risk of Parkinson’s disease: A preliminary investigation of standard occupational codes in twins discordant for disease, Neurology, 60(Suppl. 1):A 415 (Abstract), 2003.
51. Ciechanover, A., Schwartz, A. L., The ubiquitin-proteasome pathway: The complexity and myriad functions of proteins death, Proc. Natl. Acad. Sci., USA, 95(6):2727-2730, 1998.
52. Jenner, P., Olanow, C. W., Understanding cell death in Parkinson’s disease, Ann. Neurol., 44(3 Suppl. 1):S72-S84, 1998.
53. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., Goedert, M., Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies, Proc. Natl. Acad. Sci., USA, 95(11):6469-6473, 1998.
54. Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D., Greene, L. A., Expression of A53T mutant but not wildtype alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death, J. Neurosci., 21(24):9549-9560, 2001.
55. Tofaris, G. K., Layfield, R., Spillantini, M.G., Alphasynuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome, FEBS Lett., 509(1):22-26, 2001.
56. Kanda, S., Bishop, J. F., Eglitis, M. A., Yang, Y., Mouradian, M. M., Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation, Neuroscience, 97(2):279-284, 2000.
57. Xu, J., Kao, S. Y., Lee, F. J., Song, W., Jin, L. W., Yankner, B. A., Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease, Nat. Med., 8(6):600-606, 2002.
58. Feany, M. B., Bender, W. W., A Drosophila model of Parkinson’s disease, Nature, 404(6776):394-398, 2000.
59. Zhang, Y., Gao, J., Chung, K. K., Huang, H., Dawson, V. L., Dawson, T. M., Parkin functions as an E2-dependent ubiquitinprotein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1, Proc. Nat.l Acad. Sci., USA, 97(24):13354-13359, 2000.
60. Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y., Takahashi, R., An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin, Cell, 105(7):891-902, 2001.
61. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., et al., Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson’s disease, Science, 293(5528):263-269, 2001.
62. Jha, N., Jurma, O., Lalli, G., Liu, Y., Pettus, E. H., Greenamyre, J. T., et al., Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson’s disease, J. Biol. Chem., 275(34):26096-26101, 2000.
63. Merad-Boudia, M., Nicole, A., Santiard-Baron, D., Saille, C., Ceballos-Picot, I., Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: Relevance to Parkinson’s disease, Biochem. Pharmacol., 56(5):645-655, 1998.
64. Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., et al., Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra, J. Neurochem., 69(3):1196-1203, 1997.
65. Sanchez-Ramos, J., Overvik, E., Overvik, A. B. N., A marker of oxyradical-mediated DNA damage (8-hydroxy-2’deoxyguanosine)is increased in the nigrostriatum of Parkinson’s disease brain, Neurodegeneration, 3(197):204, 1994.
66. Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Jenner, P., Marsden, C. D., Glutathione-related enzymes in brain in Parkinson’s disease. Ann. Neurol., 36(3):356-361, 1994.
67. Soto-Otero, R., Mendez-Alvarez, E., Hermida-Ameijeiras, A., Munoz-Patino, A. M., Labandeira-Garcia, J. L., Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: Potential implication in relation to the pathogenesis of Parkinson’s disease, J. Neurochem. 74(4):1605-1612, 2000.
68. Jenner, P., Olanow, C.W., Oxidative stress and the pathogenesis of Parkinson’s disease, Neurology, 47(6 Suppl. 3):S161-S170, 1996.
69. Agid, Y., Chase, T., Marsden, D., Adverse reactions to levodopa: Drug toxicity or progression of disease? Lancet, 351(9106):851-852, 1998.
70. Calne, D. B., The free radical hypothesis in idiopathic parkinsonism: Evidence against it, Ann. Neurol., 32(6):799-803, 1992.
71. Murer, M. G., Dziewczapolski, G., Menalled, L. B., Garcia, M. C., Agid, Y., Gershanik, O., et al., Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions, Ann. Neurol., 43(5):561-575, 1998.
72. Rajput, A. H., The protective role of levodopa in the human substantia nigra, Adv. Neurol., 86:327-336, 2001.
73. Ebadi, M., Muralikrishnan, D., Pellett, L. J., Murphy, T., Drees, K., Ubiquinone (coenzyme Q10) and complex I in mitochondrial oxidative disorder of Parkinson’s disease, Proc. West Pharmacol. Soc., 43:55-63, 2000.
74. Gu, M., Cooper, J. M., Taanman, J. W., Schapira, A. H., Mitochondrial DNA transmission of the mitochondrial defect in Parkinson’s disease, Ann. Neurol., 44(2):177-186, 1998.
75. Janetzky, B., Hauck, S., Youdim, M. B., Riederer, P., Jellinger, K., Pantucek, F., et al., Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson’s disease, Neurosci. Lett., 169(1-2):126-128, 1994.
76. Gu, M., Gash, M. T., Cooper, J. M., Wenning, G. K., Daniel, S. E., Quinn, N. P., et al., Mitochondrial respiratory chain function in multiple system atrophy, Mov. Disord., 12(3):418-422, 1997.
77. Hartmann, A., Hunot, S., Michel, P. P., Muriel, M. P., Vyas, S., Faucheux, B. A., et al., Caspase-3: A vulnerability factor and final effector in apoptotic death of opaminergic neurons in Parkinson’s disease, Proc. Natl. Acad. Sci., USA, 97(6):2875-2880, 2000.
78. Viswanath, V., Wu, Y., Boonplueang, R., Chen, S., Stevenson, F. F., Yantiri, F., et al., Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease, J. Neurosci., 21(24):9519-9528, 2000.
79. Kahns, S., Lykkebo, S., Jakobsen, L. D., Nielsen, M. S., Jensen, P. H., Caspase-mediated parkin cleavage in apoptotic cell death, J. Biol. Chem., 277(18):15303-15308, 2002.
80. Banati, R. B., Daniel, S. E., Blunt, S. B., Glial pathology but absence of apoptotic nigral neurons in longstanding Parkinson’s disease, Mov. Disord., 13(2):221-227, 1998.
81. Jellinger, K. A., Stadelmann, C. H., The enigma of cell death in neurodegenerative disorders, J. Neural. Transm., Suppl., (60):21-36, 2000.
82. Beal, M. F., Energetics in the pathogenesis of neurodegenerative disease, Trends Neurosci. 23(7):298-304, 2000.
83. Uitti, R. J., Rajput, A. H., Ahlskog, J. E., Offord, K. P., Schroeder, D. R., Ho, M. M., et al., Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease, Neurology, 46(6):1551-1556, 1996.
84. McGeer, P. L., Itagaki, S., Boyes, B. E., McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains, Neurology, 38(8):1285-1291, 1988.
85. Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., Karluk, D., Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure, Ann. Neurol., 46(4):598-605, 1999.
86. de la Fuente-Fernandez, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., Stoessl, A. J., Expectation and dopamine release: Mechanism of the placebo effect in Parkinson’s disease, Science, 293(5532):1164-1166, 2001.
87. Marsden, C. D., Parkes, J. D., “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy, Lancet, 1(7954):292-296, 1976.
88. Quinn, N., Critchley, P., Marsden, C. D., Young onset Parkinson’s disease, Mov. Disord., 2(2):73-91, 1987.
89. Rinne, U. K., Problems associated with long-term levodopa treatment of Parkinson’s disease, Acta Neurol. Scand. Suppl., 95:19-26, 1983.
90. Stocchi, F., Nordera, G., Marsden, C. D., Strategies for treating patients with advanced Parkinson’s disease with disastrous fluctuations and dyskinesias, Clin. Neuropharmacol., 20(2):95-115, 1997
91. Sweet, R. D., McDowell, F. H., The “on-off” response to chronic L-DOPA treatment of Parkinsonism, Adv.Neurol., 5:331-338, 1974.
92. Rinne, U. K., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Marti Masso, J. F., et al., Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial, The PKDS009 Study Group, Drugs, 55 Suppl. 1:23-30, 1998.
93. Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., Lang, A. E., A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa, 056 Study Group, New Engl. J. Med., 342(20):1484-1491, 2000.
94. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: Design and methods of the CALM-PD Study, Parkinson Study Group, Clin. Neuropharmacol., 23(1):34-44, 2000.
95. Huang, Z., Kumar, A., Tsui, J. K. C., COMT inhibition in Parkinson’s disease, Geriatrics and Aging, 5(4):32-35, 2002.
96. Saint-Hilaire, M. H., Feldman, R. G., The “on-off” phenomenon in Parkinson’s disease, In Joseph, A. B., Young, R. R., EEEd., Movement disorders in neurology and neuropsychiatry. Boston: Blackwell Scientific Publications, 180-184, 1999.
97. Chase, T. N., Oh, J. D., Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications, Ann. Neurol., 47(4 Suppl. 1):S122-S129, 2001.
98. de la Fuente-Fernandez, R., Lu, J. Q., Sossi, V., Jivan, S., Schulzer, M., Holden, J. E., et al., Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover, Ann. Neurol., 49(3):298-303, 2001.
99. Guldberg, H. C., Marsden, C. A., Catechol-O-methyl transferase: Pharmacological aspects and physiological role, Pharmacol. Rev., 27(2):135-206, 1975.
100. Nutt, J. G., Woodward, W. R., Beckner, R. M., Stone, C. K., Berggren, K., Carter, J. H., et al., Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients, Neurology, 44(5):913-919, 1994.
101. Mannisto, P. T., Tuomainen, P., Toivonen, M., Tornwall, M., Kaakkola, S., Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats, J. Neural. Transm., Park Dis Dement Sect, 2(1):31-43, 1990.
102. Nutt, J. G., Catechol-O-methyltransferase inhibitors for treatment of Parkinson’s disease, Lancet, 351(9111):1221-1222, 1998.
103. Entacapone improves motor fluctuations in levodopatreated Parkinson’s disease patients, Parkinson Study Group, Ann. Neurol., 42(5):747-755, 1997.
104. Ruottinen, H. M., Niinivirta, M., Bergman, J., Oikonen, V., Solin, O., Eskola, O., et al., Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson’s disease requires prolonged imaging, Synapse, 40(1):19-26, 2001.
105. Merello, M., Lees, A. J., Webster, R., Bovingdon, M., Gordin, A., Effect of entacapone, a peripherally acting catechol-Omethyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson’s disease, J. Neurol. Neurosurg. Psychiatry, 57(2):186-189, 1994.
106. Rinne, U. K., Larsen, J. P., Siden, A., Worm-Petersen, J., Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group, Neurology, 51(5):1309--1314, 1998.
107. Waters, C. H., Kurth, M., Bailey, P., Shulman, L. M., LeWitt, P., Dorflinger, E., et al., Tolcapone in stable Parkinson’s disease: Efficacy and safety of longterm treatment, The Tolcapone Stable Study Group, Neurology, 49(3):665-671, 1997.
108. Stocchi, F., Olanow, C. W., Neuroprotection in Parkinson’s disease: Clinical trials, Ann. Neurol., 53 Suppl. 3:S87-S97, 2003.
109. DATATOP: A multicenter controlled clinical trial in early Parkinson’s disease, Parkinson Study Group, Arch. Neurol., 46(10):1052-1060, 1989.
110. Effect of deprenyl on the progression of disability in early Parkinson’s disease, The Parkinson Study Group, N. Engl. J. Med., 321(20):1364-1371, 1989.
111. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease, The Parkinson Study Group, N. Engl. J. Med., 328(3):176-183, 1993.
112. Olanow, C. W., Hauser, R. A., Gauger, L., Malapira, T., Koller, W., Hubble, J., et al., The effect of deprenyl and levodopa on the progression of Parkinson’s disease, Ann. Neurol., 38(5):771-777, 1995.
113. Przuntek, H., Conrad, B., Dichgans, J., Kraus, P. H., Krauseneck, P., Pergande, G., et al., SELEDO: A 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa, Eur. J. Neurol., 6(2):141-150, 1999.
114. Hauser, R. A., Koller, W. C., Hubble, J. P., Malapira, T., Busenbark, K., Olanow, C. W., Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson’ s disease, Mov. Disord., 15(3):485-489, 2000.
115. Youdim, M. B., Weinstock, M., Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5YL)-ethyl methyl carbamate], Cell Mol. Neurobiol., 21(6):555-573, 2001.
116. Mytilineou, C., Radcliffe, P., Leonardi, E. K., Werner, P., Olanow, C. W., L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro, J. Neurochem., 68(1):33-39, 1997.
117. Tatton, W. G., Chalmers-Redman, R. M., Ju, W. J., Mammen, M., Carlile, G. W., Pong, A. W., et al., Propargylamines induce antiapoptotic new protein synthesis in serumand nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells, J. Pharmacol. Exp. Ther., 301(2):753-764, 2002.
118. Carlile, G. W., Chalmers-Redman, R. M., Tatton, N. A., Pong, A., Borden, K. E., Tatton, W. G., Reduced apoptosis after nerve growth factor and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer, Mol. Pharmacol., 57(1):2-12, 2000.
119. Tatton, W. G., Ju, W. Y., Holland, D. P., Tai, C., Kwan, M., Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis, J. Neurochem.,63(4):1572-1575, 1994.
120. Doble, A., The role of excitotoxicity in neurodegenerative disease: Implications for therapy, Pharmacol. Ther, 81(3):163-221, 1999.
121. Turski, L., Bressler, K., Rettig, K. J., Loschmann, P. A., Wachtel, H., Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-Daspartate antagonists, Nature, 349(6308):414-418, 1991.
122. Greenamyre, J. T., Eller, R. V., Zhang, Z., Ovadia, A., Kurlan, R., Gash, D. M., Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson’s disease, Ann. Neurol., 35(6):655-661, 1994.
123. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD, Parkinson Study Group, Neurology, 54(8):1583-1588, 2000.
124. Rascol, O., Olanow, C. W., Brooks, D. J., et al., A 2-year multicenter placebo-controlled, double-blind parallel group study of the effect of riluzole on Parkinson’s disease progression, Mov. Disord., 17:39, 2003.
125. Shults, C. W., Oakes, D., Kieburtz, K., Beal, M. F., Haas, R., Plumb, S., et al., Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline, Arch. Neurol., 59(10):1541-1550, 2002.
126. Rakshi, J. S., Pavese, N., Uema, T., Ito, K., Morrish, P. K., Bailey, D. L., et al., A comparison of the progression of early Parkinson’s disease in patients started on ropinirole or L-dopa: An 18F-dopa PET stud, J. Neural. Transm., 109(12):1433-1443, 2002.
127. Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S., Collins, F., GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons, Science, 260(5111):1130-1132, 1993.
128. Herbert, M. A., Hoffer, B. J., Zhang, Z., et al., Functional effects of GDNF in normal and parkinsonian rats and monkeys, In: Tuszynski, M., Kordower, J. H., Eds., CNS regeneration: Basic science and clinical advances, Academic Press, NY, 419-436, 1999.
129. Kordower, J. H., Palfi, S., Chen, E. Y., Ma, S. Y., Sendera, T., Cochran, E. J., et al., Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease, Ann. Neurol., 46(3):419-424, 1999.
130. Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., et al., Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease, Science, 290(5492):767-773, 2000.
131. Koller, W. C., Wilkinson, S., Pahwa, R., Miyawaki, E. K., Surgical treatment options in Parkinson’s disease, Neurosurg. Clin. N. Am., 9(2):295-306, 1998.
132. Hariz, M. I., Complications of deep brain stimulation surgery, Mov. Disord., 17 Suppl. 3:S162-S166, 2002.
133. Lang, A. E., Widner, H., Deep brain stimulation for Parkinson’s disease: Patient selection and evaluation, Mov. Disord., 17 Suppl. 3:S94-101, 2002.
134. Olanow, C. W., Kordower, J. H., Freeman, T. B., Fetal nigral transplantation as a therapy for Parkinson’s disease, Trends Neurosci., 19(3):102-109, 1996.
135. Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W. Y., DuMouchel, W., Kao, R., et al., Transplantation of embryonic dopamine neurons for severe Parkinson’s diseas,. N. Engl. J. Med., 344(10):710-719, 2001.
136. Hagell, P., Piccini, P., Bjorklund, A., Brundin, P., Rehncrona, S., Widner, H., et al., Dyskinesias following neural transplantation in Parkinson’s disease, Nat. Neurosci., 5(7):627-628, 2002.
137. Huang, Z., de la Fuente-Fernandez, R., Hauser, R. A., Freeman, T. B., Sossi, V., Olanow, C. W., et al., Dopaminergic alteration in Parkinson’s patients with off-period dyskinesia following striatal embryonic mesencephalic transplant, Neurology, 60 (S1):A127, 2003.
138. Fink, J. S., Schumacher, J. M., Ellias, S. L., Palmer, E. P., Saint-Hilaire, M., Shannon, K., et al., Porcine xenografts in Parkinson’s disease and Huntington’s disease patients: Preliminary results, Cell Transplant., 9(2):273-278, 2000.
139. Bjorklund, L. M., Sanchez-Pernaute, R., Chung, S., Andersson, T., Chen, I. Y., McNaught, K. S., et al., Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model, Proc. Natl. Acad. Sci., U S A, 99(4):2344-2349, 2002.
140. Kim, J. H., Auerbach, J. M., Rodriguez-Gomez, J. A., Velasco, I., Gavin, D., Lumelsky, N., et al., Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease, Nature, 418(6893):50-56, 2002.
141. Watts, R. L., Raiser, C. D., Stover, N. P., Cornfeldt, M. L., Schweikert, A. W., Allen, R. C., et al., Stereotaxic intrastriatal implantation of retinal pigment epithelial cells attached to microcarriers in six advanced parkinson disease patients; two year follow-up, Neurology, 60(S1):A164-A165, 2003.